Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Aarnoutse

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
The Journal of Antimicrobial Chemotherapy|June 28, 2021
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reportingZahra Sadouki, Timothy D McHugh, Rob Aarnoutse, et al.
AIDS and Behavior|March 3, 2025
Prevalence and Determinants of Viral Suppression in Young People Living with HIV on Antiretroviral Therapy in Southern Africa: A Cross-Sectional Analysis of HIV Survey Data of 2020 and 2021Takondwa Charles Msosa, Alinune Kabaghe, Hussein Hassan Twabi, et al.
Tuberculosis (Edinburgh, Scotland)|February 13, 2026
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation studyEmily Behrens, Niklas Köhler, Max Münchow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled TrialFiona V Cresswell, David B Meya, Enock Kagimu, et al.
Frontiers in Immunology|October 29, 2020
Perspective for Precision Medicine for TuberculosisChristoph Lange, Rob Aarnoutse, Dumitru Chesov, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary TuberculosisElin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Trials|April 21, 2018
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trialChishala Chabala, Anna Turkova, Margaret J Thomason, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
Antibiotics (Basel, Switzerland)|February 25, 2023
Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of AgeMaria Goretti López-Ramos, Joan Vinent, Rob Aarnoutse, et al.
The Journal of Infection|February 4, 2023
Pretomanid-resistant tuberculosisNiklas Koehler, Sönke Andres, Matthias Merker, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
The Journal of Antimicrobial Chemotherapy|June 28, 2021
Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reportingZahra Sadouki, Timothy D McHugh, Rob Aarnoutse, et al.
AIDS and Behavior|March 3, 2025
Prevalence and Determinants of Viral Suppression in Young People Living with HIV on Antiretroviral Therapy in Southern Africa: A Cross-Sectional Analysis of HIV Survey Data of 2020 and 2021Takondwa Charles Msosa, Alinune Kabaghe, Hussein Hassan Twabi, et al.
Tuberculosis (Edinburgh, Scotland)|February 13, 2026
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation studyEmily Behrens, Niklas Köhler, Max Münchow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2021
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled TrialFiona V Cresswell, David B Meya, Enock Kagimu, et al.
Frontiers in Immunology|October 29, 2020
Perspective for Precision Medicine for TuberculosisChristoph Lange, Rob Aarnoutse, Dumitru Chesov, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary TuberculosisElin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Trials|April 21, 2018
Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trialChishala Chabala, Anna Turkova, Margaret J Thomason, et al.
British Journal of Clinical Pharmacology|September 4, 2024
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patientsTom G Jacobs, Hylke Waalewijn, Lily Houlden, et al.
Antibiotics (Basel, Switzerland)|February 25, 2023
Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of AgeMaria Goretti López-Ramos, Joan Vinent, Rob Aarnoutse, et al.
The Journal of Infection|February 4, 2023
Pretomanid-resistant tuberculosisNiklas Koehler, Sönke Andres, Matthias Merker, et al.
Pageof 7